摘要
目的探讨紫杉醇联合洛铂经介入栓塞给药化疗宫颈癌的近远期疗效分析。方法选取宫颈癌患者78例,根据其治疗方案分成观察组和对照组,各组39例。对照组给予紫杉醇脂质体175 mg/m~2和洛铂80 mg/m~2分别稀释于250 ml的5%葡萄糖注射液中,以静脉滴注方式给药;观察组患者以动脉造影方式选取子宫动脉和肿瘤血管,并以动脉穿刺插管构建给药通路,将175 mg/m~2的紫杉醇脂质体和80 mg/m~2注射用洛铂溶解于10 ml的5%葡萄糖注射液中,混匀后经穿刺导管注入血管,两组均治疗3个疗程。观察两组患者近期临床疗效、不良反应及远期生存情况。结果观察组患者临床治疗总有效率为84. 61%较对照组(58. 97%)高,差异有统计学意义(P <0. 05);两组患者的不良反应、局部复发与转移情况相比,差异均无统计学意义(P> 0. 05);观察组患者3年的生存率为69. 23%较对照组(46. 15%),生存时间[(27. 65±0. 83)月]较对照组[(20. 49±1. 45)月]长,差异有统计学意义(P <0. 05)。结论紫杉醇联合洛铂经介入栓塞给药化疗宫颈癌患者疗效确切,具有较高安全性,且可提高患者的远期生存率。
Objective To investigate the near and long term effect of paclitaxel combined with luoplatinum in the treatment of cervical cancer by interventional embolization. Methods 78 cases of cervical cancer were selected and divided into the observation group and the control group according to the treatment plan,with 39 cases in each group. The control group was given5% Glucose Injection paclitaxel liposome 175 mg/m~2 and lobaplatin 80 mg/m~2 respectively diluted in 250 ml,by intravenous administration; the patients in the observation group were selected by angiography of uterine artery and tumor blood vessels,and to construct artery catheterization administration pathway,175 mg/m~2 paclitaxel liposome and 80 mg/m~2 solution of Lobaplatin for Injection 5% Glucose Injection 10 ml,after mixing the catheter into a blood vessel,two groups were treated for 3 courses. The short-term clinical effects,adverse reactions and long-term survival of the two groups were observed. Results The observation group clinical total effective rate was 84. 61% compared with the control group( 58. 97%),the difference was statistically significant( P < 0. 05); compared with the adverse reactions of the two groups of patients,local recurrence and metastasis,there were no significant differences( P > 0. 05); the patients in the observation group were 3 year survival rate was 69. 23% compared with the control group( 46. 15%),the survival time of [( 27. 65 ± 0. 83) months]than in the control group [( 20. 49 ± 1. 45) months],the difference was statistically significant( P < 0. 05). Conclusion Paclitaxel Combined with luoplatinum is effective and safe in the treatment of cervical cancer,and it can improve the long-term survival rate of patients.
引文
[1]Lim AW,Forbes LJ,Rosenthal AN,et al.Measuring the nature and duration of symptoms of cervical cancer in young women:developing an interview-based approach[J].BMCWomens Health,2013,13(1):357-366.
[2]Downs L.Advances in cervical cancer treatment[J].Gynecol Oncol,2011,121(121):431-433.
[3]李慧,郭荣,岳莎莎,等.紫杉醇联合卡铂同期放疗对高危险早期宫颈癌患者术后的临床疗效及安全性研究[J].中国实用医药,2016,11(35):17-19.
[4]Shuster A,Huynh TJ,Rajan DK,et al.Response evaluation criteria in solid tumors(RECIST)criteria are superior to european association for study of the liver(EASL)criteria at 1month follow-up for predicting long-term survival in patients treated with transarterial chemoembolization before liver transplantation for hepatocellular cancer[J].J Vasc Interv Radiol,2013,24(6):805-812.
[5]Gutzmer R,Wollenberg A,Ugurel S,et al.Cutaneous side effects of new antitumor drugs:clinical features and management[J].Dtsch Arztebl Int,2012,109(8):133-140.
[6]Eskander RN,Tewari KS.Immunotherapy:an evolving paradigm in the treatment of advanced cervical cancer[J].Clin Ther,2015,37(1):20-38.
[7]Du TG,Kidd M.Prospective quality of life study of south african women undergoing treatment for advanced-stage cervical cancer[J].Clin Ther,2015,37(10):2324-2331.
[8]Lapresa M,Parma G,Portuesi R,et al.Neoadjuvant chemotherapy in cervical cancer:an update[J].Expert Rev Anticancer Ther,2015,15(10):1171-1181.
